Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial
Last Updated: Monday, June 27, 2022
Long-term outcomes from the phase 3 ABCSG-18 trial of 3,425 postmenopausal patients with early HR+ breast cancer on aromatase inhibitors (AI) show that adjuvant denosumab every six months during AI therapy is safe and reduces treatment-induced clinical fractures.
Advertisement
News & Literature Highlights